Anti-CD28/anti-HMV-MAA bispecific antibody (Eberhard-Karls-Universitaet Tuebingen)

N/A

Report date: 2026/03/19 16:46:18

Base Information

Drug NameAnti-CD28/anti-HMV-MAA bispecific antibody (Eberhard-Karls-Universitaet Tuebingen)

Drug Alias Namer28MrM28

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT-cell-specific surface glycoprotein CD28 modulators

TargetsT-cell-specific surface glycoprotein CD28

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesEberhard-Karls Universitaet Tuebingen

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesEberhard-Karls Universitaet Tuebingen

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A